KR20090120499A - Ｃｂ２ 수용체 매개 통증의 치료 방법 - Google Patents

Ｃｂ２ 수용체 매개 통증의 치료 방법 Download PDF

Info

Publication number
KR20090120499A
KR20090120499A KR1020097020429A KR20097020429A KR20090120499A KR 20090120499 A KR20090120499 A KR 20090120499A KR 1020097020429 A KR1020097020429 A KR 1020097020429A KR 20097020429 A KR20097020429 A KR 20097020429A KR 20090120499 A KR20090120499 A KR 20090120499A
Authority
KR
South Korea
Prior art keywords
alkyl
halogen
hydroxy
optionally substituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097020429A
Other languages
English (en)
Korean (ko)
Inventor
밍더 샤
크리스토퍼 엠. 플로레스
마크 제이. 맥시락
케빈 폴 파블릭
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20090120499(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20090120499A publication Critical patent/KR20090120499A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020097020429A 2007-03-21 2008-02-27 Ｃｂ２ 수용체 매개 통증의 치료 방법 Withdrawn KR20090120499A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89601407P 2007-03-21 2007-03-21
US60/896,014 2007-03-21

Publications (1)

Publication Number Publication Date
KR20090120499A true KR20090120499A (ko) 2009-11-24

Family

ID=39766329

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097020429A Withdrawn KR20090120499A (ko) 2007-03-21 2008-02-27 Ｃｂ２ 수용체 매개 통증의 치료 방법

Country Status (14)

Country Link
US (1) US20080234347A1 (https=)
EP (1) EP2139326A4 (https=)
JP (1) JP2010522181A (https=)
KR (1) KR20090120499A (https=)
CN (1) CN101677556A (https=)
AR (1) AR065800A1 (https=)
AU (1) AU2008229264A1 (https=)
CA (1) CA2681381A1 (https=)
CL (1) CL2008000827A1 (https=)
MX (1) MX2009010162A (https=)
PE (1) PE20090062A1 (https=)
TW (1) TW200901972A (https=)
UY (1) UY30973A1 (https=)
WO (1) WO2008115671A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101787116B1 (ko) * 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
EP3541371A4 (en) * 2017-11-15 2020-07-22 Panag Pharma Inc. METHODS OF TREATING INTERSTITIAL CYSTITIS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698335A4 (en) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
TW200602324A (en) * 2004-03-24 2006-01-16 Janssen Pharmaceutica Nv Tetrahydro-indazole cannabinoid modulators cross reference to related applications
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
PL1937259T3 (pl) * 2005-09-23 2012-04-30 Janssen Pharmaceutica Nv Heksahydrocykloheptapirazolowe modulatory receptora kanabinoidowego

Also Published As

Publication number Publication date
TW200901972A (en) 2009-01-16
CA2681381A1 (en) 2008-09-25
US20080234347A1 (en) 2008-09-25
MX2009010162A (es) 2009-10-12
CN101677556A (zh) 2010-03-24
JP2010522181A (ja) 2010-07-01
PE20090062A1 (es) 2009-01-26
EP2139326A4 (en) 2011-06-15
WO2008115671A1 (en) 2008-09-25
CL2008000827A1 (es) 2008-09-26
AU2008229264A1 (en) 2008-09-25
UY30973A1 (es) 2008-09-30
EP2139326A1 (en) 2010-01-06
AR065800A1 (es) 2009-07-01

Similar Documents

Publication Publication Date Title
TWI585083B (zh) 用於預防及／或治療手術後疼痛的σ配子
PT2646025T (pt) Uso de ligandos sigma na dor do cancro do osso
US9931346B2 (en) Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations
US20160058771A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
AU2015360006B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
JPS63185927A (ja) 薬物中毒治療のための医薬
KR20090120500A (ko) Ｃｂ２ 수용체 매개 통증의 치료 방법
KR20090120499A (ko) Ｃｂ２ 수용체 매개 통증의 치료 방법
US20090215850A1 (en) Method for treating cb2 receptor mediated pain
AU2013329865B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor
WO2004007503A1 (ja) 悪心・嘔吐の治療または予防剤
EP3711757B1 (en) Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
JP2008512415A (ja) 中枢神経障害性疼痛の治療のためのアリール（またはヘテロアリール）アゾリルカルビノールの誘導体
EA015503B1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения черепно-мозговых травм
CN106456641A (zh) 眼后段疾病的预防或治疗剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid